Loading…
← CockpitCompetitor Analysis › DIA.WA Diagnostyka S.A.Open in the cockpit ↗

Diagnostyka S.A.DIA.WACompetitor analysis, valuation and peers

Poland · PLN·Health Care›Medical/Nursing Services

Poland's largest medical diagnostics laboratory chain, providing lab testing and diagnostic imaging services nationwide.

≈ Poland's largest medical diagnostics lab chain, like a Polish Quest DiagnosticsMomentum weak 35
Mkt cap
$1.28B
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$1.20M
20-day average traded
Fwd P/E
19.5×
forward earnings
ROIC−WACC
+7.9 pp
WACC 9.5%
Hurdle
-12 pp
Req g minus delivered
Next earnings
8 days
26 Nov 2026
Close · PLNPLN 152.00
1D+0.7%
1W-0.7%
1M-1.9%
3M-7.9%
6M-5.7%
YTD-11.1%
1Y-15.8%
ATR %2.0%
52w lowhigh26.9% off high

What Diagnostyka does

Poland's largest medical diagnostics laboratory chain, providing lab testing and diagnostic imaging services nationwide.

Paid either by the national health fund under contracts with set volumes, or directly by private patients and employers; lab tests are the bulk of the work, with imaging and genetics on top. It has grown mostly by buying smaller laboratories in a fragmented Polish market.

In one line: Poland's largest medical diagnostics lab chain, like a Polish Quest Diagnostics.

Products and services

  • Laboratory testing services
  • Diagnostic imaging (radiology)
  • Genetic testing

Customers

  • Patients
  • Hospitals and physicians
  • NFZ (Polish national health fund)

Where it sits in the supply chain

  • Healthcare services
  • Diagnostic laboratory testing
  • Imaging & genetic testing

What could go right

  • Rising diagnostic test volumes from aging population
  • Private healthcare growth in Poland

What could go wrong

  • NFZ reimbursement pricing pressure
  • Competition from other lab chains

Moat: narrow (scale, distribution, brand). Largest diagnostic lab network in Poland with scale and NFZ contract relationships.

Headquarters: Krakow, Poland · Founded: 2001 · Employees: 7,635

Named competitors

  • Medicover MCOV-B.ST
  • Synlab private or unlisted
  • ALAB Laboratoria private or unlisted

Diagnostyka at a glance

Size Diagnostyka (DIA.WA) is a Poland Health Care company (Medical/Nursing Services) with a market value of $1.28B, the 35th largest of 82 Poland companies the cockpit tracks. Shares closed at PLN 152.00 on 18 Nov 2026.

Performance Over six months the shares fell 5.7%, against +17.1% for the median peer and +14.0% for the Poland market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 19.2% over the last twelve months (peer median +7.9%); the operating margin is 14.5% (peer median 3.5%).

Valuation It trades at 19.5× forward earnings against a peer median of 29.4× (6th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -12 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 7.9 points above its cost of capital (9.5% WACC).

Next results Next results expected around 26 Nov 2026 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 117DIA.WA 92
Six months, rebased to 100: Diagnostyka against the median of its 20 peers (local-currency closes).

Diagnostyka financials

Reported figures in PLN; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenuePLN 2.58BPLN 2.41BPLN 1.95BPLN 1.59BPLN 1.44B
Revenue growth—+24%+23%+11%—
Gross profitPLN 433MPLN 429MPLN 355MPLN 265MPLN 278M
EBITDAPLN 596MPLN 581MPLN 481MPLN 378MPLN 362M
Net incomePLN 255MPLN 252MPLN 223MPLN 123MPLN 167M
Free cash flowPLN 251MPLN 281MPLN 229MPLN 214MPLN 177M
Capital expenditurePLN 202MPLN 205MPLN 133MPLN 81.3MPLN 89.4M
Total debtPLN 1.22BPLN 1.08BPLN 969MPLN 850MPLN 721M

Quarterly statements and history in the cockpit →

Diagnostyka competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%PNTGOPKMETROPOLISCLARILMRI1833NUTXGDRXUSPH4544TDOCAGLWGSAMBEASNDA688315AHCOPSNLVIJAYAREGDIA.WA6-month return →1-month return →
Up and to the right = strong over both horizons. Diagnostyka is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×60×PNTGMETROPOLISCLARILMRI1833NUTXGDRXUSPH4544AGLWGSAMBEA688315VIJAYAREGDIA.WARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Diagnostyka is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%PNTGMETROPOLISCLARI1833NUTXTDOCDIA.WAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Diagnostyka is the large dot.

Diagnostyka competitors and peer comparison

Head to head with its named competitors (DIA.WA vs MCOV-B.ST)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Diagnostyka DIA.WA$1.28B-6%+19%15%19.5×7.3%
Medicover MCOV-B.ST$3.87B+21%+3%7%36.1×19.6%

How Diagnostyka compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Diagnostyka against its 20 peers (data as of 18 Nov 2026)
MeasureDIA.WAPeer medianRank in peer set
1-month return-1.9%+1.3%9th lowest of 21
6-month return-5.7%+17.1%6th lowest of 21
Distance from 52-week high-26.9%-22.2%9th lowest of 21
Revenue growth (TTM)+19.2%+7.9%5th highest of 21
Operating margin14.5%3.5%4th highest of 21
Forward P/E19.5×29.4×6th cheapest of 16
Growth the price implies (Req g, 7 yrs)7.3%11.5%7th least demanding of 15
Growth delivered (Del g)+18.9%+11.8%4th highest of 15
Hurdle (Req g minus delivered)-11.6 pp+0.8 pp3rd least demanding of 15
ROIC minus cost of capital+7.9 pp-3.8 pp3rd highest of 19
EV / EBITDA10.7×10.7×8th cheapest of 15
Net debt / EBITDA2.0×1.3×8th most indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%19.5×7.3%+18.9%
Pennant PNTGUnited States$1.26B+1%+39%6%23.7×20.7%+19.4%
OPKO Health OPKUnited States$1.25B+37%-22%-29%n/an/an/a
Metropolis Healthcare METROPOLIS.NSIndia$1.25B+11%+20%18%44.5×32.4%+10.5%
Clariane CLARI.PAFrance$1.32B-20%+1%6%8.2×6.8%+6.5%
Lumexa Imaging LMRIUnited States$1.35B+89%+8%2%16.0×n/an/a
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%33.5×3.5%-5.1%
Nutex Health NUTXUnited States$1.19B+42%-19%39%6.5×-18.0%+253.5%
GoodRx GDRXUnited States$1.15B+33%-2%12%10.6×6.3%+7.7%
U.S. Physical Therapy USPHUnited States$1.42B+53%+10%10%29.4×18.8%+13.0%
H.U.Group 4544.TJapan$1.44B+24%+1%3%39.9×9.7%+2.1%
Teladoc Health TDOCUnited States$1.47B+24%-2%-5%n/a-6.4%+18.3%
agilon health AGLUnited States$1.52B+12%+2%-2%34.1×n/an/a
GeneDx WGSUnited States$1.56B+16%+15%-14%54.2×n/an/a
Ambea AMBEA.STSweden$1.59B+28%+11%9%15.2×1.1%+7.7%
Sonida Senior Living SNDAUnited States$1.59B-11%+70%-8%n/an/an/a
Novogene 688315.SSChina$1.01B+13%+6%7%44.8×13.9%+8.2%
AdaptHealth AHCOUnited States$1.01B-30%-3%3%n/a16.8%+25.2%
Personalis PSNLUnited States$1.62B+88%+17%-157%n/an/an/a
Vijaya Diagnostic Centre VIJAYA.NSIndia$1.69B+18%+24%32%63.0×40.4%+16.7%
Regis Healthcare REG.AXAustralia$962M-28%+17%4%25.3×13.3%+14.4%

Questions

Who are Diagnostyka's main competitors?
Named competitors: Medicover (MCOV-B.ST), Synlab (private or unlisted), ALAB Laboratoria (private or unlisted). The cockpit's measured peer set (industry) also includes Pennant (PNTG), OPKO Health (OPK), Metropolis Healthcare (METROPOLIS.NS), Clariane (CLARI.PA), Lumexa Imaging (LMRI), Ping An Healthcare and Technology (1833.HK).
Is Diagnostyka expensive compared with its peers?
On forward p/e it trades at 19.5× against a peer median of 29.4×, 6th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -12 pp: the price already allows for a slowdown.
How has Diagnostyka stock performed?
Over six months to 18 Nov 2026 the shares returned -5.7% against +17.1% for the median peer; over one year -15.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.